sparfloxacin has been researched along with Experimental Lung Inflammation in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, Z; Lei, Y; Ma, Y; Wang, K; Xia, D; Xu, P; Zhu, T | 1 |
| Iwagaki, A; Matsumoto, K; Nagatake, T; Oishi, K; Pollack, M; Ponglertnapagorn, P; Siadak, A; Sonoda, F; Watanabe, K | 1 |
| Ambrose, PG; Nightingale, CH; Owens, RC; Quintiliani, R | 1 |
| Chuck, SK; Jung, R; Martin, SJ; Messick, CR; Meyer, JM; Pendland, SL | 1 |
| Acusta, A; Dorr, MB; Dowzicky, M; Nadler, H; Talbot, GH | 1 |
| Goss, TF; Najib, MM; Stein, GE | 1 |
| Schentag, JJ | 1 |
| Iwagaki, A; Kobayashi, S; Matsumoto, K; Nagatake, T; Oishi, K; Sonoda, F | 1 |
3 review(s) available for sparfloxacin and Experimental Lung Inflammation
| Article | Year |
|---|---|
New generations of quinolones: with particular attention to levofloxacin.
Topics: Anti-Infective Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Pneumonia; Quinolones | 1997 |
Levofloxacin and sparfloxacin: new quinolone antibiotics.
Topics: Absorption; Anti-Infective Agents; Bronchitis; Drug Interactions; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Ofloxacin; Pneumonia; Quinolones; Sinusitis; Skin Diseases; Urinary Tract Infections | 1998 |
Sparfloxacin: a review.
Topics: Anti-Infective Agents; Bronchitis; Community-Acquired Infections; Fluoroquinolones; Humans; Pneumonia | 2000 |
1 trial(s) available for sparfloxacin and Experimental Lung Inflammation
| Article | Year |
|---|---|
Comparison of the in vitro activity of and pathogen responses to sparfloxacin with those of other agents in the treatment of respiratory tract, urinary tract, and skin and skin-structure infections.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Community-Acquired Infections; Fluoroquinolones; Humans; Pneumonia; Respiratory Tract Infections; Skin Diseases, Bacterial; Urinary Tract Infections | 1999 |
5 other study(ies) available for sparfloxacin and Experimental Lung Inflammation
| Article | Year |
|---|---|
Neutrophil membranes coated, antibiotic agent loaded nanoparticles targeting to the lung inflammation.
Topics: Animals; Anti-Bacterial Agents; Cell Membrane; Cell Survival; Drug Delivery Systems; Drug Liberation; Fluoroquinolones; Humans; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Nanoparticles; Neutrophils; Particle Size; Pneumonia; Surface Properties | 2020 |
Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Infective Agents; Antibodies, Monoclonal; Bacteremia; Cell Movement; Female; Flagella; Fluoroquinolones; Humans; Lipopolysaccharides; Lung; Mice; Mice, Inbred ICR; Neutropenia; Opsonin Proteins; Phagocytosis; Pneumonia; Pseudomonas Infections; Quinolones; Serotyping | 1993 |
Sparfloxacin and levofloxacin.
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Clinical Trials as Topic; Drug Eruptions; Fluoroquinolones; Gastrointestinal Diseases; Humans; Levofloxacin; Ofloxacin; Photosensitivity Disorders; Pneumonia; Quinolones | 1997 |
Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Azithromycin; Cefaclor; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Erythromycin; Fluoroquinolones; Humans; Models, Economic; Outpatients; Pneumonia; Treatment Outcome | 2000 |
Effects of the combination of lipopolysaccharide-specific monoclonal antibodies and sparfloxacin against Pseudomonas aeruginosa pneumonia in neutropenic mice.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Antibodies, Monoclonal; Cyclophosphamide; Drug Therapy, Combination; Female; Fluoroquinolones; Immunoglobulin G; Injections, Intravenous; Lipopolysaccharides; Lung; Mice; Mice, Inbred ICR; Neutropenia; Pneumonia; Pseudomonas Infections; Quinolones | 1992 |